Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Looking forward to knowing who this is..... ;)
I have my suspicions, and have only added on the way up.....all the way from 1p.
Absolutely stunning progress over the past couple of years, and if things come to fruition could be a massive year for SP & Company moving forward.
Already hugely undervalued, and a great BoD.
Strong Buy.
1,000,000 share buy....funds now loading up ;)
Market mechanics. Hold Long and strong, add on the dips. Its a really simple game.
NDA reveal....and this is going up to 40p+ in short order. IMO.
Big Shareholders have been adding ;)
NDA....so close to reveal...and could be a big one!
A very good buy price. IMO
My calculations now have IP alone for Diagnostics worth in excess of £10 Billion +, if you understand the monumental shift about to happen due to Affimers in the diagnostic world.
Its a long term hold for me, only adding on the way up and watching a big buyout at some point, or watch this grown into a global monster. Happy to hold 10 years either way.
IMO, DYOR etc.
Long term holder here. Fantastic news today, and has been an easy hold since last April (Only adding).
The Affimer platform for Diagnostics with delivery of CE Mark is almost impossible to value at this point. It will be interesting to see how the market reacts to £Billion deals and licensing over the coming months, as the MCAP is now very much out of touch with just the value of the Diagnostics Affimer platform alone.
All timed very conveniently with May 17th opening up.
GL All.
The Affimer IP alone within Diagnostics is now worth £Multi-Billion+.
Affimers will be the 'Intel' of the Diagnostics testing globally for the foreseeable future.
You cannot now put a price on Affimer IP it that valuable. Thats before any revenues...and revenue potential.
There's a Bruker webinar on Bams today at 4pm for those who are interested.
https://www.drugtargetreview.com/webinar/84323/bead-assisted-mass-spectrometry-assay-platform-for-targeted-proteomics/?target=register&campaign_source=BrukerLinkedIn#register
ABOUT THIS WEBINAR
Bead Assisted Mass Spectrometry (BAMS™) is an assay platform that combines immuno-affinity capture on magnetic beads with detection by MALDI-TOF mass spectrometry for multiplexed, targeted proteomic assays. Almost any protein target is accessible as long as a specific affinity reagent (ie, antibody) is available.
The webinar will focus on the detailed description of the workflow and case studies of BAMS™ assays developed for targets relevant to neurology and virology. MALDI-TOF data resulted from the assays will be discussed in depth.
Learning outcomes of this webinar:
Discover a novel, multiplexed, customisable assay platform for targeted proteomics and biomarker research
Understand how the BAMS™ assay platform can be used to characterise complex combinations of post-translational modifications (PTMs) and proteoforms of the protein target of interest
Learn from BAMS™ assay case studies relevant to neurology and virology.
Sounds like they are going to speak about the SARS-CoV-2 assay
GLA
Fantastic. On the way to £Billion MCAP.
This breaks 30p today ;-)
Could end up £10,000,000 + to ffwd.
What's the MCAP?
Plus shares in the monster curaleaf
100 million. IMO.
IMG ;)